Prodesse Receives Additional Convertible Debt Funding

Prodesse announces it has received additional funding from existing and new investors

WAUKESHA, WI (August 23, 2005) – Prodesse, Inc. announced today that a group of its core investors, plus three new accredited individuals, have provided additional funding. This offering is composed of a debt instrument convertible into equity at increasing prices over a 3-year period.

Tom Shannon, CEO, commented, "With Prodesse now nearly cash-flow positive and our new manufacturing facility completed, this additional funding will be used to secure additional licenses, increase capacity for strategic collaborations, and for application for FDA clearance on tests using our reagents. Prodesse's customers repeatedly tell us that we are on the leading edge of the accelerating molecular diagnostics revolution, with our multiplexing capabilities being particularly valuable. Our investors seem to agree. Prodesse remains the only company in the world to have successfully commercialized multiplex Real Time PCR reagents from which labs have developed assays capable of detecting and differentiating three organisms and an internal control."

About Prodesse
Prodesse is a biotechnology company focused on developing analyte specific reagents that can be used by CLIA certified laboratories to develop assays for detecting infectious disease pathogens. The Company's reagents incorporate proprietary technology that allows for the detection of multiple pathogens. Prodesse currently offers nine different multiplex products covering 33 different organisms. The company’s products can be used on a variety of detection platforms. The Company sells its reagents to laboratories throughout the US and the world, and also operates a CLIA certified laboratory for testing services in the Midwest area. For more information about Prodesse and its products, call 888-589-6974 or go to www.prodesse.com.